Wave Life Sciences Ltd. (WVE) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello and welcome to Wavelife Science, the second quarter 2025 earnings call. We ask that you please hold all questions until the completion of the formal remarks, at which time you will be given instructions for the question and answer session. Also as a reminder, this conference is being recorded today. I will now pass the call over to Kate Rausch, Vice President of Corporate Affairs and Investor Relations. Thank you, operator. And good morning to everyone on the call. Earlier this morning, we issued a press release outlining our second quarter 2025 earnings update. Joining me today with prepared remarks are Dr. Paul Polno, President and Chief Executive Officer, Dr. Eric Ingelson, Chief Scientific Officer, and Kyle Moran, Chief Financial Officer. Dr. Chris Wright, Chief Medical Officer is also in the room and will be available for questions. The press release issued this morning is available on the investor section of our website, .wavelifesciences.com. Before we begin, I would like to remind you that discussions during this conference call will include forward-looking statements. These statements are subject to several risks and uncertainties that could cause our actual results to differ materially from those described in these forward-looking statements. The factors that could cause actual results to differ are discussed in the press release issued today and in our SEC filings. We undertake no obligation to update or revise any forward-looking statement for any reason. I'd now like to turn the call over to Paul. Thanks, Kate. Good morning, and thank you all for joining us on today's call. We enter the second half of 2025 with strong momentum as we continue on our mission of unlocking the broad potential of RNA medicines using our proprietary and -in-class oligonu...